Joint promotional activities for Allegion\u00ae Eyelid Cream 0.5% in the Japanese market with Santen. The target area is medical institutions other than ophthalmology. If disclosure reasons arise affecting the consolidated earnings forecast for the fiscal year ending March 2027, notification will be made promptly. The product is world\u2019s first once-daily application formulation.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4569","jir_company_name":"Kyorin Pharmaceutical Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2606\u2606","jir_publication_date":"2026-08-03","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/08\/4569-20260803-01.pdf","jir_short_summary":"Joint promotional activities for Allegion\u00ae Eyelid Cream 0.5% in the Japanese market with Santen. The target area is medical institutions other than ophthalmology. If disclosure reasons arise affecting the consolidated earnings forecast for the fiscal year ending March 2027, notification will be made promptly. The product is world\u2019s first once-daily application formulation.","jir_summary":"### Overview of the news\nKyorin Pharmaceutical will commence promotional activities for Allegion\u00ae Eyelid Cream 0.5% from August 17, 2026. A joint promotional agreement was signed with Santen on July 13, 2026, with Santen handling manufacturing, sales, and ophthalmology-area promotions, while Kyorin Pharmaceutical will promote to medical institutions outside the ophthalmology field. The aim is to expand treatment options for allergic conjunctivitis and improve patient QoL.\n\n### Financial impact and future outlook\nAs for the impact on the consolidated earnings forecast for the fiscal year ending March 2027, the company will promptly notify if there are any disclosure-related reasons. At present, no specific financial figures are available.","jir_financial_highlights":"Sales: Unknown (Unknown)","jir_category":"","jir_hashtags":"#Kyorin Pharmaceutical Co., Ltd., #IR, #JapanStocks","jir_key_figures":"Promotion start date for Allegion\u00ae Eyelid Cream 0.5%: 2026-08-17\nJoint promotional agreement signing date: 2026-07-13\nDisclosure policy for impact on the FY2027 earnings forecast: Will promptly notify upon disclosure trigger","jir_meta_title":"\u3010Kyorin Pharmaceutical Co., Ltd.\u3011Joint promotional start for Allegion eyelid cream \uff5c August 2026","jir_meta_description":"Kyorin Pharmaceutical starts promotional activities for Allegion\u00ae Eyelid Cream 0.5%. Joint promotional agreement with Santen; expansion to medical institutions outside ophthalmology. Will notify stakeholders of any earnings impact for FY2027 when disclosure reasons arise.","jir_og_title":"Kyorin Pharmaceutical\uff5cJoint promotional start for Allegion Eyelid Cream","jir_og_description":"Kyorin Pharmaceutical starts joint promotional activities for Allegion Eyelid Cream with Santen. Expanding to non-ophthalmology areas to improve QoL. Earnings impact will be notified when disclosure is warranted.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":16660,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"general_ir","footnotes":""},"sector":[],"importance":[],"class_list":["post-93455","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n